Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07313085
Starting soon Observational

Mechanisms of Fecal Incontinence in Wolfram Syndrome

NCT07313085 · tracked via the Priya Life Science France tracker
Sponsor
Hôpital Necker-Enfants Malades
Phase
Observational
Started
2025-12-20
Last updated
2025-12-31

Condition(s) studied

Wolfram SyndromeFecal Incontinence

Investigational drug(s) / intervention(s)

Retrospective case-control analysis

Retrospective case-control analysis: retrospective analysis of data

Study summary

In order to clarify the mechanism of fecal incontinence in in Wolfram syndrome and to characterize its risk factors, the examiner will reviewed the files of patients followed in a Reference Center for Rare Diseases in Ophthalmology.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Wolfram syndrome Exclusion Criteria: * no information concerning fecal incontinence in data records

Primary outcome measure(s)

  • Urinary disorders — The date at the baseline
    number of patients with urinary disorder in each group according to the group

Trial sites (1)

FacilityCityRegionStatus
HEGP Paris France

More Hôpital Necker-Enfants Malades trials in France

Looking for VUS to Confirm Dominant Wolfram-like Syndrome Instead of Recessive Wolfram Syndrome Active, not recruiting
Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients Recruiting
Metabolomics Analysis According to the Retinal Nerve Fiber Layer in Patients With NOHL Mutations (MétabOCT) Recruiting

Other trials for the same condition

Mechanisms of Action on Rectal Motricity of Intrarectal Botulinum Toxin Injections Recruiting
Skeletal Muscle-derived Cell Implantation for Treatment of Fecal Incontinence Recruiting
Evaluation of the Efficacy and Safety of Autologous Fat Injection Into the Intersphincter Space in Fecal Incontinence: a Randomized, Placebo-controlled, Cross-over, Double-blind Trial Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07313085 on ClinicalTrials.gov ↗ ← All trials in France